Lantus Insulin Program And Patient Support Resources

Oct. 9, 2025, 12:12 a.m.

Tags: lantus

Introduction

Lantus is a long-acting insulin analog used to help manage blood sugar levels in individuals with type 1 and type 2 diabetes. While Lantus is not typically offered as a free sample due to its status as a prescription medication, the manufacturer, Sanofi, provides various patient support programs, cost-saving options, and educational resources to assist patients in accessing and using the medication effectively. These initiatives include prescription savings programs, instructional materials, and guidance on proper storage and administration of the medication. This article outlines the available resources and assistance programs related to Lantus, with a focus on the information provided by the manufacturer in its official resources for healthcare professionals and patients.

Understanding Lantus and Its Uses

Lantus (insulin glargine injection) is a long-acting insulin analog designed to improve glycemic control in both type 1 and type 2 diabetes patients. It works by helping the body use glucose more effectively and should be administered once daily at the same time. Lantus is not recommended for the treatment of diabetic ketoacidosis, a serious condition requiring immediate medical attention. Patients should consult with their healthcare providers before starting treatment with Lantus to ensure it is appropriate for their condition and to understand the proper dosage and administration techniques.

The Lantus SoloSTAR® pen is a disposable, single-patient-use, prefilled insulin pen designed for convenience and accuracy. It features a large print dosing window, a push-button injection system, and small, thin needles for easier use. Patients should follow all instructions provided in the accompanying leaflet to ensure accurate dosing and avoid complications such as improper blood glucose control.

Important Safety Information

Several important safety considerations apply to the use of Lantus. Patients should not use Lantus during episodes of low blood sugar (hypoglycemia) or if they are allergic to insulin or any of its inactive ingredients. Additionally, it is crucial not to share needles, insulin pens, or syringes with others, as this can lead to the transmission of blood-borne diseases. Patients are also advised not to reuse needles to prevent infection and ensure accurate dosing.

Before beginning treatment with Lantus, patients should inform their healthcare providers of any pre-existing medical conditions such as liver or kidney problems, pregnancy plans, or breastfeeding intentions. Patients should also rotate their injection sites to reduce the risk of lipodystrophy (pitted or thickened skin) and localized cutaneous amyloidosis (skin with lumps). Repeated injections in affected areas may lead to hyperglycemia, while sudden changes in injection sites may result in hypoglycemia.

Proper Use and Storage of the Lantus SoloSTAR® Pen

The Lantus SoloSTAR® pen is designed to be used as directed by a healthcare professional. Patients should carefully review the instructions provided in the leaflet that accompanies the pen to ensure accurate and safe use. Key steps in using the SoloSTAR® pen include checking the insulin for clarity and expiration, attaching a new needle before each use, performing a safety test, selecting the appropriate dose, injecting the medication, and properly disposing of the needle after each use.

The SoloSTAR® pen should be stored in cool conditions (between 36 and 46 degrees Fahrenheit, or 2 and 8 degrees Celsius) until first use. Once removed from cool storage, the pen can be used for up to 28 days at room temperature (up to 86 degrees Fahrenheit, or 30 degrees Celsius). It is important not to use the pen after the expiration date printed on the label or to expose it to light or extreme temperatures. Used SoloSTAR® pens should be discarded according to local regulations.

Patient Support and Educational Resources

Sanofi provides a range of print materials and educational resources to help patients understand and manage their treatment with Lantus. These materials include instructions for using the SoloSTAR® pen, guidance on blood glucose monitoring, and information on the proper administration and storage of the medication. Patients can access these resources through the Lantus website or by consulting with their healthcare providers.

Additionally, the Lantus Valyou Savings Program offers financial assistance to eligible patients. Under this program, commercially insured patients may pay as low as $0 and no more than $99 for a 30-day supply of Sanofi insulins, including Lantus. Patients without insurance may also be eligible for savings through this program. It is important to review the terms and eligibility restrictions for the program to determine if it is applicable to a specific patient’s situation.

Prescription and Administration Guidelines

Lantus should only be used under the supervision of a healthcare provider, as changes in insulin regimen—such as strength, manufacturer, type, injection site, or method of administration—may require adjustments in dosage or concomitant medications. Patients should not attempt to modify their insulin regimen without consulting their healthcare provider.

The SoloSTAR® pen is designed to deliver the dose that is dialed in, and patients should follow all steps in the instruction leaflet to ensure accurate dosing. It is important to keep the pen cap on between uses and to store the pen properly to maintain its effectiveness. Patients should also avoid using the pen in areas where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred, or damaged.

Limitations and Precautions

Lantus is contraindicated in patients with hypersensitivity to insulin glargine or any of its excipients. It should not be used during episodes of hypoglycemia, and patients should always monitor their blood glucose levels when receiving treatment with insulin. It is also important to note that Lantus should not be diluted or mixed with any other insulin or solution, as this may alter its effectiveness and lead to unpredictable results.

Patients should never administer Lantus via an insulin pump or intravenously, as this can result in severe hypoglycemia. Additionally, repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia. Patients should be advised to rotate injection sites and closely monitor for hypoglycemia if they change injection sites.

Conclusion

While Lantus is not typically offered as a free sample, Sanofi provides various patient support programs and resources to help individuals with diabetes access and manage their treatment. These programs include prescription savings options, educational materials, and guidance on the proper use and storage of the Lantus SoloSTAR® pen. Patients are encouraged to consult with their healthcare providers to determine if Lantus is appropriate for their condition and to understand the proper administration techniques. By following the manufacturer’s guidelines and utilizing the available resources, patients can effectively manage their diabetes and improve their overall health outcomes.